MedTrace Logo

Adipose-derived Stem Cells (ADSCs) for Moderate to Severe Chronic Kidney Disease

NCT02933827 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2024-02-09

No results posted yet for this study

Summary

1. To assess the safety of allogeneic injection of expanded ADSCs to patients with Moderate to Severe Chronic Kidney Disease
2. To assess the efficacy of allogeneic injection of expanded ADSCs to patients with Moderate to Severe Chronic Kidney Disease

Conditions

  • Moderate to Severe Chronic Kidney Disease

Interventions

DRUG

ELIXCYTE

Adipose-derived stem cells (ADSCs)

Sponsors & Collaborators

  • UnicoCell Biomed CO. LTD

    lead INDUSTRY

Principal Investigators

  • Mai-Szu Wu, PhD · Taipei Medical University Shuang Ho Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2019-04-23
Completion
2023-06-21
FDA Drug
Yes

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02933827 on ClinicalTrials.gov